Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2014-04-28 Board/Management Inform…
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Board/Management Information 2014
Board/Management Information Classification · 99% confidence The document is very short (497 characters) and announces that Flemming Steen Jensen, a Group Director and member of the executive management, has chosen to resign from his position after 14 years at ALK. This constitutes an announcement of a change in senior management. Based on the definitions, this aligns perfectly with the 'Board/Management Information' category.
2014-04-28 Danish
Regulatory Filings 2014
Regulatory Filings Classification · 100% confidence The document is a press release dated April 25, 2014, announcing a strategic collaboration between ALK and Eddingpharm for the sale and distribution of ALK's allergy products in China. It details the terms of the agreement, the products involved (Soluprick® SQ and Alutard SQ®), quotes from the CEOs, and mentions the context of a Danish-Chinese partnership conference. This type of announcement, detailing a significant business development, partnership, or strategic move that is not a standard periodic financial report (like 10-K or IR) or a specific insider transaction (DIRS) or dividend notice (DIV), falls best under the general category for significant corporate news that isn't explicitly covered elsewhere. Since it is a major business development announcement, it is most appropriately classified as a Regulatory Filing (RNS) as a general catch-all for significant, non-standard announcements, or potentially a Capital/Financing Update (CAP) if the upfront payment was substantial, but the primary focus is the strategic partnership itself. Given the options, RNS serves as the best fit for a general, material business announcement that doesn't match the more specific categories like ER, IR, or CAP (which usually implies fundraising/debt issuance). The document length (4264 chars) is not short enough to definitively trigger the RPA rule based on the 'announcement of a report' criteria.
2014-04-25 Danish
M&A Activity 2014
M&A Activity Classification · 99% confidence The document text announces a collaboration agreement between ALK and Eddingpharm regarding sales and distribution of ALK's allergy products in China. It details the terms, products involved (Soluprick®, Alutard SQ®), the duration, and the expected minor positive effect on ALK's 2014 financial outlook. This content describes a significant business transaction or strategic partnership, which falls under corporate actions that are not explicitly covered by the core financial reports (10-K, IR, ER) or specific corporate governance filings (DEF 14A, DIRS). Since it is a material business announcement that doesn't fit the specific categories like M&A (TAR) or Financing (CAP), and it is a formal press release style announcement, the most appropriate general category is Regulatory Filings (RNS), which serves as a catch-all for significant, non-standard announcements.
2014-04-25 English
Report Publication Announcement 2014
Report Publication Announcement Classification · 98% confidence The document is very short (1003 characters) and announces the future release of a financial report ('delårsrapport første kvartal (Q1) 2014' - Interim report Q1 2014) scheduled for May 8, 2014. It also announces a subsequent conference call and mentions that the associated presentation will be available shortly before the call starts. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement regarding the publication of a report or presentation points towards a Report Publication Announcement (RPA). It is not the report itself (IR or ER), nor is it the presentation (IP) or the transcript (CT), but the notice *about* their release.
2014-04-23 Danish
Report Publication Announcement 2014
Report Publication Announcement Classification · 98% confidence The document is titled "Company release No 17/2014" and explicitly states: "Release date of three-month interim report (Q1) 2014 for ALK" and "On Thursday 8 May 2014, ALK... releases its interim report for the three months ended 31 March 2014." This indicates the document is an announcement about the upcoming release of a quarterly financial report (Interim Report/Q1). Since the document itself is short (2633 chars) and serves to announce the publication date and details of a conference call regarding the financial results, it fits the definition of a Report Publication Announcement (RPA). It is not the comprehensive Interim Report (IR) itself, nor is it the Earnings Release (ER) which typically contains the key figures.
2014-04-23 English
Regulatory Filings 2014
Regulatory Filings Classification · 100% confidence The document is a press release dated April 17, 2014, announcing that the US FDA has approved the registration application for RAGWITEK®. It details the significance of the approval, mentions a milestone payment from Merck (ALK's partner), and consequently updates ALK's financial guidance for 2014 (EBITDA forecast). This type of announcement, focusing on a specific regulatory event (FDA approval) and its immediate financial consequence (milestone payment and guidance update), is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a specific, material event announcement rather than a comprehensive periodic report (like 10-K or IR), and it is not explicitly a management discussion (MDA) or a call transcript (CT), it fits best as an Earnings Release (ER) which often includes key operational and financial highlights following a major event. However, given the focus is purely on a partnership milestone and regulatory approval, and it is not a standard quarterly earnings report, it could also be classified as a Regulatory Filing (RNS) or a Capital/Financing Update (CAP) due to the financial guidance change. Comparing the options, 'ER' is often used for material news that impacts financial outlook, even if not tied to the standard quarterly cycle. Since it is a specific, material announcement that directly leads to a financial guidance update, ER is a strong candidate. If it were purely about the partnership structure without the guidance update, it might lean towards CAP or RNS. Given the explicit update to EBITDA expectations, ER is the most appropriate fit among the provided choices for material, non-periodic financial news.
2014-04-17 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.